COVID-19 Vaccine Trial Put On Hold Because of Possible Adverse Reaction
The New York Times is reporting that a study volunteer in the U.K. developed transverse myelitis.
One of the leaders in the race to develop a COVID-19 vaccine has suffered a setback because a participant in the vaccine’s phase 3 trial developed a serious condition that might be related to vaccine.
The New York Times is reporting that a study volunteer in the U.K. developed transverse myelitis, a condition characterized by inflammation of the spinal cord. According to an National Institute of Neurological Disorders and Stroke fact sheet about transverse myelitis, the causes can include a number of different autoimmune disorders, an abnormal immune response to cancer, and viral, bacterial, and fungal infections.
Stat broke the news about the possible adverse reaction and the pause in the enrollment in the AstraZeneca's phases 3 study yesterday.
In response to Stat's story, AstraZeneca put out a statement that said it had voluntarily paused vaccination. The statement described the stoppage as a “routine action, which has to happen whenever there is a potentially unexplained illness," and cautioned that in "large trials illnesses will happen by chance."
AstraZeneca announced on Aug. 31 that it was starting to enroll study volunteers in the United States with a goal of recruiting up to 30,000 participants. The trial is designed so some people are randomized to get two doses of the vaccine — known temporarily as AZD1222 — four weeks apart and others, a saline solution.
The Times reported that the vaccine, which was developed by University of Oxford researchers, is in phase 2/3 trials in England and phase 3 trials in Brazil, South African and the United States.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Ohio’s Medicaid Work Requirement Efforts Aim to Boost Engagement, Avoid Coverage Loss
April 18th 2025Maureen Corcoran, director of the Ohio Department of Medicaid, believes the work requirement policy can be both a financial and moral effort to improve the lives of Medicaid consumers.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Why Better Data and Awareness Matters for Medicaid Work Requirements
April 17th 2025With policymakers considering work requirements for Medicaid eligibility, Jennifer Haley, principal research associate in the Health Policy Division at the Urban Institute, said it’s more important than ever to understand how those changes could unintentionally cause harm, particularly when data systems fall short and public awareness is limited.
Read More
